-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $25

Benzinga·02/24/2026 15:52:27
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $23 to $25.